Journey Medical (DERM) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Journey Medical (DERM) over the past year, losing 4.5% versus a loss of 21.2%. Lifecore Biomedical is the larger company by market cap ($243.5 million vs $169.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | LFCR |
|---|---|---|
| Share price | $5.99 | $6.43 |
| Market cap | $169.06M | $243.55M |
| 1-day change | +0.67% | -0.23% |
| YTD return | -22.83% | -21.27% |
| 1-year return | -21.19% | -4.45% |
| 5-year return | — | -34.35% |
| EPS (TTM) | $-0.22 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $8.98 |
| 52-week low | $4.31 | $3.63 |
| Distance from 52-week high | -37.31% | -28.45% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +129.55% | -2.26% |
| Average volume | 182.16K | 289.19K |
| Shares outstanding | 22.22M | 37.91M |
| Employees | 58 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed DERM by 16.7 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
DERM vs LFCR FAQ
Which is bigger, Journey Medical or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $243.55M compared with $169.06M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or LFCR?
LFCR returned -4.45% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.